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A key factor involved in the processing of histone pre-mRNAs in the nucleus and translation of mature histone mRNAs
in the cytoplasm is the stem–loop binding protein (SLBP). In this work, we have investigated SLBP nuclear transport and
subcellular localization during the cell cycle. SLBP is predominantly nuclear under steady-state conditions and localizes
to the cytoplasm during S phase when histone mRNAs accumulate. Consistently, SLBP mutants that are defective in
histone mRNA binding remain nuclear. As assayed in heterokaryons, export of SLBP from the nucleus is dependent on
histone mRNA binding, demonstrating that SLBP on its own does not possess any nuclear export signals. We find that
SLBP interacts with the import receptors Imp/Imp and Transportin-SR2. Moreover, complexes formed between SLBP
and the two import receptors are disrupted by RanGTP. We have further shown that SLBP is imported by both receptors
in vitro. Three sequences in SLBP required for Imp/Imp binding were identified. Simultaneous mutation of all three
sequences was necessary to abolish SLBP nuclear localization in vivo. In contrast, we were unable to identify an in vivo
role for Transportin-SR2 in SLBP nuclear localization. Thus, only the Imp/Imp pathway contributes to SLBP nuclear
import in HeLa cells.
INTRODUCTION
The stem–loop binding protein (SLBP) is an evolutionarily
conserved RNA binding protein involved in the metabolism
of metazoan replication-dependent histone mRNAs (Wang
et al., 1996; Martin et al., 1997; Marzluff and Duronio, 2002).
Although the majority of mRNA 3 ends result from a cleav-
age and polyadenylation reaction, those of replication-de-
pendent histone mRNAs are formed by a unique mechanism
characterized by endonucleolytic cleavage after a conserved
stem–loop sequence (Marzluff and Duronio, 2002). SLBP is
involved in the 3 end cleavage reaction in the nucleus
(Dominski and Marzluff, 1999) and in histone mRNA trans-
lation in the cytoplasm (Gallie et al., 1996; Sanchez and
Marzluff, 2002).
SLBP is a cell cycle-regulated protein, which accumulates
only during S phase, correlating with the production of
histones during times of DNA synthesis (Whitfield et al.,
2000). In late G1 phase, SLBP levels increase through acti-
vating the translation of SLBP mRNA (Whitfield et al., 2000).
Subsequently, as cells approach G2 phase, SLBP levels are
reduced by proteasome-mediated degradation (Whitfield et
al., 2000; Zheng et al., 2003). Replication-dependent histone
mRNAs similarly accumulate during S phase and are rap-
idly degraded upon completion of DNA synthesis (Marzluff
and Duronio, 2002).
Many proteins and protein/RNA complexes, which are
synthesized or assembled in the cytoplasm, have essential
functions in the nucleus. Consequently, active transport
mechanisms are in place to ensure their nuclear localization.
Transport of cargoes between the nuclear and cytoplasmic
compartments occurs through pores in the nuclear envelope
termed nuclear pore complexes (NPCs) and is carried out by
soluble transport receptors or karyopherins (Gorlich and
Kutay, 1999). The majority of known transport receptors
belong to a family of evolutionarily conserved proteins
called Importin -like transport receptors (Fried and Kutay,
2003; Mosammaparast and Pemberton, 2004). The similari-
ties shared by these proteins include a Ran binding domain
(see below) and the ability to bind NPCs.
The process of nuclear transport involves the small GTP-
ase Ran, which is differentially bound to GTP and GDP in
the nucleus and cytoplasm. Import receptors associate with
their nuclear transport substrates in the cytoplasm (Fried
and Kutay, 2003; Mosammaparast and Pemberton, 2004).
After translocation to the nuclear side of the NPC, nuclear
RanGTP binds to the receptor in the import complex, caus-
ing release of the cargo. Thus, import receptor–substrate
interactions are favored in the cytoplasm where RanGTP
levels are low.
A number of specific sequence motifs that confer binding
to import receptors have been identified. Examples include
the classical basic nuclear localization sequence (NLS) (Ding-
wall et al., 1982; Kalderon et al., 1984), the M9 domain (Siomi
and Dreyfuss, 1995), and the phosphorylated arginine-serine-
rich (RS) domain, which are recognized by the heterodimeric
import receptor Importin/Importin (Imp/Imp) (Gorlich,
1997), Transportin (Pollard et al., 1996), and Transportin-SR2
(Lai et al., 2001), respectively. These signals are highly specific
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for their cognate importins, whereas other signals exist that can
be recognized by multiple receptors, including receptors such
as Transportin and Imp. The best-defined signal of this sec-
ond category is the -like transport receptor binding domain of
ribosomal protein L23a, a very basic region to which different
importins can bind. Multiple import pathways exist not only
for ribosomal proteins (Jakel and Gorlich, 1998; Muhlhausser et
al., 2001) but also for core histones as shown in both mamma-
lian cells and yeast (Rout et al., 1997; Schlenstedt et al., 1997;
Mosammaparast et al., 2001; Muhlhausser et al., 2001).
The simplest mode of nuclear import, characteristic of
most import receptors, involves the direct association of an
import receptor with its cargo. However, there are examples
of receptors that use adapter proteins to mediate substrate
binding. Nuclear import of NLS-containing substrates by the
Imp/Imp heterodimer involves association of a cargo
with the adapter Imp (Adam and Gerace, 1991; Gorlich et
al., 1994; Moroianu et al., 1995a) and NPC binding by Imp
(Adam and Gerace, 1991; Chi et al., 1995; Moroianu et al.,
1995a,b). In the nucleus, RanGTP binds to Imp, causing the
displacement of Imp from Imp and the subsequent re-
lease of the NLS cargo from Imp (Rexach and Blobel, 1995;
Gorlich et al., 1996). A feature specific for Imp/Imp-me-
diated import (Ribbeck et al., 1999) is that RanGTP binding
of Imp also induces the dissociation of Imp from nucleo-
porins (Rexach and Blobel, 1995; Gorlich et al., 1996). After
import complex disassembly in the nucleus, Imp is ex-
ported to the cytoplasm by the export receptor CAS (Gorlich
et al., 1997; Kutay et al., 1997a), and Imp migrates back to
the cytoplasm in an export receptor-independent manner
(Gorlich et al., 1997; Izaurralde et al., 1997).
In this study, we have identified the nuclear import re-
ceptors that mediate SLBP import in vitro and have mapped
the sequences in SLBP essential for its nuclear localization in
vivo. We have also examined the subcellular localization of
SLBP during the cell cycle.
MATERIALS AND METHODS
Molecular Cloning
Hemagglutinin (HA)-SLBP has been described previously (Zheng et al., 2003).
The HA-SLBPSFTTP construct was generated by cloning the NcoI/XbaI frag-
ment from His6-pcDNA3/SLBPSFTTP (Zheng et al., 2003) into HA-pcDNA3.
HA-SLBPRR was generated by standard site-directed mutagenesis techniques.
SLBP deletion and point mutants used for in vitro translation were con-
structed in the pXFRM/SLBP plasmid (Wang et al., 1999). pXFRM contains
the SP6 promoter, and the 5 and 3 untranslated regions (UTRs) of -globin
as well as a 50-nt polyA stretch downstream of the -globin 3 UTR. Deletion
and site-directed mutagenesis were performed using standard PCR and clon-
ing methods.
The baculovirus His6-gluatathione S-transferase (GST)-SLBP expression
plasmid (HTb/GST-SLBP) was made by amplifying the GST-SLBP sequence in
pQE-60/GST-SLBP and cloning it into the KpnI and XbaI sites of pFastBac HTb.
The GFP-SLBP mammalian expression vector (GFP-SLBP) was constructed
by insertion of the SLBP open reading frame into the BamHI and EcoRI sites
of the green fluorescent protein (GFP) plasmid (pK7) kindly provided by I.
Macara (Department of Cell Biology, University of Virginia School of Medi-
cine, Charlottesville, VA) (McKiernan et al., 1996). GST-GFP-SLBP was made
by cloning GST from pGEX-2T into the XbaI site upstream of GFP in GFP-
SLBP. Site-directed mutagenesis and the combining of mutations were carried
out using standard PCR and cloning methods. Annealed oligos containing the
simian virus 40 (SV40) NLS (PKKKRKVED) or sequences required for SLBP
nuclear localization (KRKL [RYKRKLLIN], RKRR [LGRKRRADG], and
KVRH [PTKVRHMDS]) were cloned into the BamHI and EcoRI sites down-
stream of GFP in the GST-GFP vector to yield GST-GFPSV40, GST-GFPKRKL,
GST-GFPRKRR and GST-GFPKVRH.
The coding region of human Transportin-SR2 was amplified by PCR by
using HeLa cell cDNA as a template. The PCR fragment was cloned into the
BamHI/XmaI sites of pQE30 to yield pQE30-TrnSR-2.
RNA Interference and Plasmid Transfections
HeLa cells were seeded at a density of 8.5  104 cells/ml in a total volume of
500 l (DMEM supplemented with 10% fetal bovine serum) in a single well of
a 24-well plate (Greiner Bio-One, Frickenhausen, Germany). The following
day, the cells were transfected with small interfering RNA (siRNA) at a final
concentration of 100 nM. The siRNA transfection protocol was performed
essentially as described previously (Wagner and Garcia-Blanco, 2002). Briefly,
3 l of LipofectAMINE 2000 (Invitrogen, Carlsbad, CA) was added to 12 l of
Opti-MEM (Invitrogen) and allowed to incubate at room temperature for 7
min. After incubation, the mixture was added to a solution containing 47 l
of Opti-MEM and 3 l of the 20 M siRNA stock. The reaction was further
incubated for 25 min at room temperature. Subsequently, 38 l of Opti-MEM was
added to the reaction, and 100 l of the transfection mixture was pipetted onto
the cells. The following day, the cells were split 1:2 from a 24-well plate to a
six-well plate containing coverslips. On the next day, the cells were retransfected
with siRNA in an identical manner as described above, except that the final
concentration of siRNA was 50 nM. Two days later, the cells were either har-
vested and lysed for Western blot analysis or fixed for immunostaining. The
siRNA sequence used to target SLBP is 5-GAGAGAGAAAAUCAUCAUC-3,
whereas the C2 siRNA has been described previously (Wagner and Garcia-
Blanco, 2002).
Cell lines expressing HA-SLBPwt, HA-SLBPRR, and HA-SLBPSFTTP were
produced by transfecting HeLa cells (in a six-well plate) with 1 g of DNA
(pcDNA3/HA-SLBPwt, pcDNA3/HA-SLBPRR, and pcDNA3/HA-SLBPSFTTP)
by using the LipofectAMINE reagent (Invitrogen). One day after transfection,
the cells were split into media containing 0.5 mg/ml G418 (Geneticin, Invitro-
gen). The cells were kept under selection until separate colonies could be
observed by eye and were either pooled (HA-SLBPRR) or used to make clonal
cell lines (HA-SLBPwt and HA-SLBPSFTTP) by using the limiting dilution
method.
For the in vivo localization studies using either GFP- or GST-GFP–tagged
SLBPs, 2  105 HeLa cells/well were plated onto coverslips in a six-well plate
1 d before transfection. The following day, cells were transfected with 100 ng
of plasmid DNA by using the LipofectAMINE 2000 reagent (Invitrogen)
according to the manufacturer’s protocol.
Protein Purification and Labeling
Baculovirus expressed His6-GST-SLBP was purified by nickel-nitrilotriacetic
acid (NTA) chromatography by using standard procedures. Reducing agents
were excluded from all of the buffers used during the purification procedure.
Proteins were labeled on cysteines with an equimolar amount of Alexa 488
(Molecular Probes, Eugene, OR) for 1 h on ice. Unincorporated Alexa 488 was
removed by passage over a MicroSpin G-50 column (Amersham Biosciences,
Piscataway, NJ) equilibrated in 50 mM Tris, pH 7.5, 200 mM potassium
acetate, and 2 mM magnesium chloride. Escherichia coli expression and puri-
fication of RanQ69L, Imp, Imp, Transportin, Imp5, and Imp7 were per-
formed as described previously (Gorlich et al., 1996; Kutay et al., 1997b; Jakel
and Gorlich, 1998). Trn-SR2 was expressed in E. coli XL1 (pBS161) at 22°C.
Cells were lysed by sonication in 50 mM Tris-HCl, pH 7.5, 700 mM NaCl, 10
mM MgCl2, 5% glycerol, and 5 mM -mercaptoethanol. Purification was
performed by chromatography on nickel-NTA agarose, followed by MonoQ
and gel filtration in 50 mM Tris-HCl, pH 7.5, 100 mM potassium acetate, and
2 mM dithiothreitol. Proteins tagged with two copies of the IgG binding
domain or “z” domain of Protein A (termed “zz”) were prepared in a manner
similar to their His-tagged counterparts.
In Vitro Binding Assays
[35S]Methionine-labeled SLBPs were produced by in vitro translation using
the coupled transcription translation kit by Promega. Binding assays using
purified recombinant zz-Trn-SR2 or zz-Imp/Imp and [35S]SLBP were car-
ried out as follows: zz-Imp and Imp (70 pmol each) were first bound to one
another for 20 min on ice. Depending on the relative amounts of each of the
labeled proteins, between 10 and 12 l of each in vitro translation reaction
was mixed with 70 pmol of zz-Trn-SR2 or zz-Imp/Imp heterodimers. The
reactions were incubated for 30 min on ice and were subsequently diluted to
100 l to achieve a final concentration of 225 mM NaCl, 20 mM HEPES, pH 7.0,
0.001% Triton X-100, and 2 mM Mg(OAc)2 (binding buffer). When included in the
reaction, the final concentration of RanQ69L was 10 M. Control reactions
contained the [35S]SLBP and binding buffer. The binding reactions were then
cleared of any aggregated material by centrifugation, and the supernatant was
transferred to a fresh tube containing 10 l of packed IgG-Sepharose beads
(Amersham Biosciences) preequilibrated in the binding buffer. After a 30-min
incubation, the beads were washed four times with the binding buffer and eluted
with 50 l of 2 sample buffer. One-fifth of the eluted material was run on a 10%
SDS-PAGE alongside 1/25 of the input. The gel was stained with Coomassie Blue
to determine whether the same amount of receptor in each binding reaction was
recovered. Subsequently, the gel was dried and exposed to a PhosphorImager
screen.
In reactions using purified SLBP, 70 pmol of purified import receptor was
incubated with 150 pmol of GST-SLBP in a final volume of 100 l. The conditions
for the binding of complexes to IgG-Sepharose beads and complex recovery were
the same as for the binding assay using in vitro-translated SLBP.
In Vitro Import Assays
In vitro transport reactions into the nuclei of digitonin semipermeabilized
cells were performed essentially as described previously (Jakel et al., 1999).
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Fluorescently labeled GST-SLBP (1 M) was preincubated for 5 min on ice
with equimolar amounts of purified import receptors. The import buffer
contained 20 mM HEPES, pH 7.5, 100 mM potassium acetate, 2 mM magne-
sium acetate, 0.5 mM EGTA, and 250 mM sucrose and was supplemented
with an energy-regenerating system and Ran mix (Kutay et al., 1997b). Import
was performed for 15 min at room temperature. The samples were then
washed once with import buffer, fixed with 3.7% paraformaldehyde (PFA),
and visualized by fluorescence microscopy.
Cell Synchronization and Drug Treatment
One hundred thousand cells per well of a six-well plate were seeded onto
coverslips. On the next day, thymidine was added to the media at a final
concentration of 2 mM. After 19 h, the cells were washed twice with 1
phosphate-buffered saline (PBS) and supplemented with media lacking thy-
midine. The cells were incubated for 9 h in the absence of thymidine and
subsequently exposed to a second treatment with thymidine for 16 h. At this
time, the cells were washed twice with 1 PBS and supplemented with fresh
media lacking thymidine. Coverslips were fixed and cells were harvested
every 2 h after release from the second thymidine block. Cells exposed to the
proteasome inhibitor MG132 (50 M) were treated 4 h after release from the
second thymidine block and harvested 6 h later.
Lysate Preparation and Western Blotting
Cells were lysed in an NP-40 lysis buffer (0.1% NP-40, 20 mM Tris, pH 7.0, 150
mM NaCl, 10% glycerol, and 1 mM phenylmethylsulfonyl fluoride) for 10 min
at 4°C. Lysates were cleared by centrifugation at 4°C for 10 min at maximum
speed. Unless otherwise indicated in the figure legend, 40 g of total protein
was resolved on a 10% SDS-PAGE, transferred to nitrocellulose, and probed
with the anti-SLBP or anti-GFP antibody (BD Biosciences Clontech, Palo Alto,
CA) at a dilution of 1:1000. Detection was carried out using a horseradish
peroxidase-conjugated anti-rabbit or anti-mouse antibody (Jackson Immu-
noResearch Laboratories, West Grove, PA; diluted 1:10,000) and an enhanced
chemiluminescence system (Amersham Biosciences).
Immunostaining and GFP Fusion Protein Localization
HeLa cells grown on coverslips were washed briefly with 1 PBS and fixed
with 3.7% PFA. After permeabilization with 0.5% Triton X-100 and washing
with 1 PBS, the coverslips were incubated for 1 h with either the anti-SLBP
or anti-HA antibody diluted 1:100 in 1 PBS and 1% bovine serum albumin.
The monoclonal anti-HA antibody was a kind gift of Dr. Yue Xiong (Depart-
ment of Biochemistry and Biophysics, University of North Carolina at Chapel
Hill, Chapel Hill, NC). Detection was carried out using either a rhodamine
anti-rabbit (Jackson ImmunoResearch Laboratories) or Cy3-conjugated anti-
mouse antibody (Jackson ImmunoResearch Laboratories). Cells were subse-
quently postfixed with 3.7% PFA and counterstained with 0.1 g/ml 4,6-
diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, St. Louis, MO). Images
were taken using a Zeiss confocal microscope and the LSM 510 software.
The localization of the GFP and GST-GFP–tagged proteins was assessed 2 d
after transfection. Coverslips were washed briefly with 1 PBS, and the cells
were fixed with 3.7% PFA. The cells were washed with PBS and permeabil-
ized with 0.5% Triton X-100. Counterstaining with DAPI was carried out as
described above.
Heterokaryon Assay
Heterokaryon assays were carried out essentially as described previously
(Zhang and Xiong, 2001). Human U2-OS cells were transfected with plasmid
DNA expressing the GFP-SLBP fusion proteins. After 12 h of incubation with
the plasmid, cells were washed twice with prewarmed PBS to remove un-
transfected DNA. The cells were then trypsinized, mixed with wild-type
mouse embryonic fibroblast (MEF) cells at a 1:1 ratio, and seeded onto a new
dish. After another 12 h of incubation, the cells were rinsed once with PBS and
covered with a solution of 50% (wt/vol) polyethylene glycol (PEG8000;
Sigma-Aldrich) for 2 min at 37°C to induce cell fusion. After washing three
times with PBS to remove the PEG, fused cells were continuously cultured in
DMEM/10% fetal bovine serum media for 90 min. Cycloheximide (50 g/ml;
Sigma-Aldrich) was added to the culture 15 min before and immediately after
cell fusion to block de novo protein synthesis. Subsequent cell fixation,
permeabilization, and immunostaining followed standard immunofluores-
cence procedures. The cells were stained with a mouse antibody recognizing
human but not murine Ku nuclear antigen to distinguish human and murine
nuclei.
RESULTS
Localization of SLBP during the Cell Cycle
Previous cell fractionation studies have indicated that SLBP
is present in both the nuclear and cytoplasmic fractions
(Hanson et al., 1996; Whitfield et al., 2004), consistent with its
involvement in histone pre-mRNA processing in the nucleus
and histone mRNA translation in the cytoplasm. To directly
assess the localization of SLBP in intact cells, immunostain-
ing was carried out on asynchronously growing HeLa cells
using a polyclonal anti-SLBP antibody raised against the
C-terminal 13 amino acids of the protein (Wang et al., 1996).
SLBP was found to be predominantly nuclear, with some
variability in the ratio of nuclear-to-cytoplasmic staining
from cell to cell (Figure 1A, left). Consistent with the cell
cycle-regulated expression of SLBP, the intensity of the sig-
nal generated by the SLBP antibody was not homogeneous
in an asynchronous population of cells.
Western blotting of total HeLa cell extract resolved in
denaturing SDS polyacrylamide gels shows that the SLBP
antibody cross-reacts with two other proteins (75 and 90 kDa
apparent molecular mass) in addition to SLBP (Figure 5B).
To determine the specificity of the immunofluorescence sig-
nal generated with the SLBP antibody, we reduced the levels
of SLBP by using RNA interference and performed immu-
nostaining. Western analysis revealed that SLBP levels were
reduced by at least 90% by an siRNA targeting the SLBP
mRNA and not by a control siRNA (Figure 1B). The majority
of the cells transfected with the SLBP siRNA exhibited only
background staining with the SLBP antibody (Figure 1A,
right). Thus, we conclude that, in intact HeLa cells assayed
by immunofluorescence, the SLBP antibody recognizes only
Figure 1. Specificity of the anti-SLBP antibody for SLBP in intact
HeLa cells as assayed by immunofluorescence. (A) HeLa cells trans-
fected with either the C2 control siRNA (left) or the S2 siRNA
specific for SLBP (right) were subject to immunostaining with the
SLBP antibody. (B) To evaluate the knockdown resulting from the
S2 siRNA, Western blot analysis with the SLBP antibody was per-
formed using lysates made from C2 (lanes 1–5) or SLBP (lane 6)
siRNA-transfected cells. In lanes 1, 5, and 6, 10 g of total protein
was loaded, whereas in lanes 2, 3, and 4, 5, 2, and 1 g of total
protein was used, respectively. The asterisk marks the migration of
the 75-kDa protein that cross-reacts with the SLBP antibody and
serves as an internal loading control.
J. A. Erkmann et al.
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SLBP and that the cross-reacting proteins are only detected
in Western blots.
Because the staining pattern for SLBP in asynchronously
growing cells (Figures 1A, left, and 2A, top left) was some-
what heterogeneous, we tested whether the variability could
be explained by differences in cell cycle position. HeLa cells
were synchronized using a double thymidine block proto-
col, which arrests cells at the beginning of S phase. These
cells have accumulated SLBP, which is not present during
G2, mitosis, or early G1 (Whitfield et al., 2000). After release
from the double thymidine block, the cells progress synchro-
nously through S phase and into G2 phase. Samples were
collected at two-hour intervals after release of the cells from
the second thymidine block. The cell cycle expression profile
of the endogenous SLBP was analyzed by Western blotting
by using the SLBP antibody (Figure 2B). Before and 2 h after
release from the double thymidine block, SLBP was predom-
inantly nuclear, with very little present in the cytoplasm
(Figure 2A, 0 and 2 h). However, as cells progressed through
S phase, there was an increase in the proportion of SLBP in
the cytoplasm (Figure 2A, 4 and 6 h), indicating that during
S phase, when histone mRNA levels are high, SLBP partially
redistributes to the cytoplasm. A similar pattern of nucleo-
cytoplasmic distribution of SLBP was observed in the fol-
lowing S phase (9 h later; our unpublished data), indicating
that the staining pattern shown in Figure 2A accurately
reflects the localization of SLBP during S phase. By 10 h after
release from the double-thymidine block, the staining of
SLBP is greatly reduced (Figure 2A, 10 h) as a result of the
regulated degradation of SLBP 8 h after release (Figure 2B).
Nondegradable SLBP Is Nuclear in G2 Phase of the Cell
Cycle
SLBP is degraded by the proteasome at the end of S phase in
a phosphorylation-dependent manner (Whitfield et al., 2000;
Zheng et al., 2003). Cells treated in late S phase with the
proteasome inhibitor MG132 accumulate phosphorylated
SLBP. To further characterize the location of SLBP present in
G2-phase cells, we performed immunostaining on cells in G2
phase that had been exposed to MG132 during S phase.
When cells were released from a double-thymidine block for
4 h and treated with MG132 for 6 h, we found that the
majority of SLBP was nuclear (Figure 2A, 10M). This result
is in contrast to our previous observations obtained by cel-
lular fractionation, where the phosphorylated SLBP that ac-
cumulates after MG132 treatment was exclusively cytoplas-
mic (Zheng et al., 2003). It is likely that this difference results
from leakage of phosphorylated SLBP from the nucleus
during cell fractionation (see Discussion).
To rule out the possibility that our results might simply
reflect that the SLBP antibody does not efficiently react with
SLBP in the cytoplasm, possibly due to inaccessibility of the
C-terminal end of the protein in this compartment, we ex-
amined the localization of an N-terminally HA-tagged SLBP
(HA-SLBPwt), by using an anti-HA antibody. It has been
previously shown that HA-SLBPwt is expressed at levels
comparable with the endogenous SLBP and its expression
profile mirrors that of the endogenous protein (Zheng et al.,
2003; Figure 2C). A clonal HA-SLBPwt-expressing cell line
stained with an HA antibody revealed that, like the endog-
enous SLBP, the HA-SLBPwt was predominantly nuclear in
unsynchronized cells (Figure 2A, asynch.). In addition, HA-
SLBPwt redistributed to the cytoplasm to a similar extent as
the endogenous protein in mid- to late S phase and was
predominantly nuclear in MG132-treated G2-phase cells
(Figure 2A, 4 h, 6 h, and 10M). Thus, these results confirm
the staining pattern observed using the SLBP antibody.
Because MG132 is a general inhibitor of the proteasome
and likely perturbs many aspects of cellular regulation, we
also used a mutant SLBP that is not degraded at the end of
S phase to study the localization of SLBP in G2 phase. A
critical sequence in SLBP responsible for its degradation at
the end of S phase has been mapped to amino acids 59–63,
containing the residues SFTTP. The two threonines in this
sequence are phosphorylated and trigger the degradation of
SLBP (Zheng et al., 2003). If this sequence is mutated to
alanine, SLBP is stable at the S/G2 transition, and persists
during G2 phase. HeLa cells stably expressing an HA-tagged
SLBP construct containing the SFTTP/AAAAA mutation
(HA-SLBPSFTTP) were synchronized (Figure 2E) and the lo-
calization of HA-SLBPSFTTP was observed with an anti-HA
antibody (Figure 2D). HA-SLBPSFTTP accumulated in the
nucleus of G2-phase cells (Figure 2D, 10 h), further demon-
strating that SLBP present in G2 phase accumulates in the
nucleus.
The RNA Binding Activity of SLBP Is Required for
Cytoplasmic Localization
The data presented so far are consistent with the presence of
SLBP in the cytoplasm being dependent on its association
with histone mRNA. In agreement with this possibility,
treatment of cells with hydroxyurea, which results in rapid
degradation of histone mRNA, results in the relocalization
of SLBP to the nucleus (Whitfield et al., 2004). To address this
issue directly, we made a two-amino acid substitution in
SLBP (R137K, R138K [HA-SLBPRR]), which is known to
severely interfere with its RNA binding activity (Dominski
et al., 2001), and subsequently examined the localization of
HA-SLBPRR during S phase. A pool of cells stably trans-
fected with HA-SLBPRR was synchronized (Figure 2F), and
the localization of the protein was examined (Figure 2A).
The HA-SLBPRR remained in the nucleus throughout the cell
cycle (Figure 2A) and was degraded at the end of S phase
(Figure 2F). These results thus demonstrate that the accu-
mulation of SLBP in the cytoplasm requires that SLBP be
able to bind to histone mRNA.
SLBP Is Imported by Transportin-SR2 and Imp/Imp In
Vitro
To identify potential SLBP import receptors, we used an in
vitro nuclear import assay with semipermeabilized HeLa
cells. A His6-tagged SLBP molecule (33 kDa) diffused into
the nucleus of permeabilized HeLa cells without addition of
any transport factors (our unpublished data). Therefore, a
GST-tagged SLBP was constructed and expressed in insect
cells. Incubation of permeabilized HeLa cells with purified,
fluorescently labeled GST-SLBP and an energy-regenerating
system did not allow for its nuclear import (Figure 3A).
However, if the import reaction was supplemented with
Trn-SR2 or Imp/Imp, SLBP accumulated in the nucleus
(Figure 3A). Significantly, Imp on its own and four other
import receptors were unable to support the accumulation
of SLBP in the nucleus. All of these receptors were active in
the import of their known cognate cargos (our unpublished
data). These results therefore demonstrate that Trn-SR2 and
Imp/Imp can import SLBP in vitro.
SLBP Binds Trn-SR2 and Imp/Imp Directly
To verify that SLBP can bind to Trn-SR2 and Imp/Imp
directly, a solution binding assay was performed. Com-
plexes between purified baculovirus-expressed GST-SLBP
and purified E. coli expressed import receptors were formed.
IgG-Sepharose beads were used to recover the complexes by
virtue of a tag containing two copies of the IgG binding
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Figure 2. Subcellular distribution of SLBP changes during S phase and is dependent on RNA binding. (A) Untransfected HeLa cells (left
two columns), a clonal cell line expressing HA-SLBPwt (center two columns) or a pool of stably transfected cells expressing HA-SLBPRR (right
two columns) were synchronized by double-thymidine block. After release from the second thymidine block, the localization of the
endogenous SLBP (left two columns) or HA-tagged SLBPs (remaining four columns) was monitored every 2 h by immunostaining with either
the anti-SLBP or anti-HA antibody. The top row shows the localization of the various SLBPs in an asynchronous population of cells and the
remaining rows show cells at different times (hours) after release from double thymidine block. The bottom row shows the localization of
the endogenous SLBP and HA-SLBPwt in cells exposed to MG132 at 4 h (S phase) and harvested 10 h (G2 phase) after release (10M). (B and
C) Western blot by using the anti-SLBP antibody to illustrate the expression profile of the endogenous SLBP (B) and HA-SLBPwt (C) in the
same cells as those shown in A. The asterisk marks the 75-kDa protein that cross-reacts with the SLBP antibody on Western blots. The arrow
indicates the phosphorylated SLBP, which accumulates when protein degradation is blocked at the end of S phase. (D) A clonal cell line
expressing HA-SLBPSFTTP was synchronized, and the localization of HA-SLBPSFTTP was determined using the anti-HA antibody as in A. (E
and F) Lysates prepared from HA-SLBPSFTTP (E) or HA-SLBPRR (panel F) expressing cells (at the indicated times postrelease from
double-thymidine block) were tested for SLBP levels by Western blot analysis by using the SLBP antibody.
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domain of protein A (z domain) fused to Trn-SR2 and Imp
(zz-Trn-SR2 and zz-Imp/Imp). Bound proteins were
eluted with SDS sample buffer and resolved on an SDS
polyacrylamide gel. Coomassie staining of the gel revealed
that both zz-Imp/Imp (Figure 3B, lane 3) and zz-Trn-SR2
(lane 5) bound GST-SLBP, whereas the IgG-Sepharose beads
alone (lane 2) did not. In addition, compared with the Imp/
Imp heterodimer, zz-Imp without Imp interacted with
SLBP only weakly (lane 4). Although the direct interaction
between SLBP and zz-Imp can be disrupted by RanQ69L
(Supplemental Figure 1), it is insufficient to support nuclear
localization of SLBP (Figure 3A). These results confirm that
the interaction between SLBP and Trn-SR2 and Imp/Imp
is direct and that Imp does not contribute substantially to
the association of SLBP with the Imp/Imp heterodimer.
RanGTP Dissociates Trn-SR2 and Imp/Imp from SLBP
Import receptor/cargo complexes are dissociated by
RanGTP in the nucleus. Consequently, we assessed the abil-
ity of RanGTP to disrupt SLBP/Trn-SR2 and SLBP/Imp/
Imp complexes. RanQ69L-GTP, a Ran mutant lacking GTP-
ase function that is constitutively GTP bound if loaded with
GTP, was used for this purpose. zz-Trn-SR2 or zz-Imp/
Imp was incubated with in vitro-translated SLBP, and the
complexes containing the radiolabeled SLBP were recovered
on IgG-Sepharose beads (Figure 3C, lanes 3 and 5). When
RanQ69L was included in the reaction, the amount of SLBP
associated with zz-Imp/Imp and zz-Trn-SR2 was re-
duced (Figure 3C, lanes 4 and 6). Dissociation of SLBP from
Imp by RanQ69L was specific because SLBP and a second
Imp substrate Kip (Sekimoto et al., 2004) were dissociated
from Imp by RanQ69L to a similar extent (Supplemental
Figure 2). These observations demonstrate that RanQ69L can
dissociate SLBP from Trn-SR2 and Imp/Imp and suggest
that the complexes formed between SLBP and Imp/Imp
or Trn-SR2 are relevant to SLBP nuclear import.
Binding of Imp/Imp to SLBP Is Mediated by Three
Different Sequences
The classical, monopartite NLS recognized by Imp consists
of a short stretch of basic residues exemplified by the SV40
large T antigen NLS (PKKKRKV) (Kalderon et al., 1984).
Two stretches of basic amino acids in the N-terminal domain
of SLBP (RKRR and KRKL) as well as one in the C-terminal
domain of the protein (KVRH) are highlighted in bold in
Figure 4A. As a first approach toward mapping the se-
quences required for binding to Imp/Imp, SLBP con-
structs were designed which either lacked the C-terminal
domain (C70) or were truncated from the N-terminal end
(N89 and N127), removing portions of the protein con-
taining the predicted binding sites. The resulting proteins
were then tested for the ability to interact with Imp/Imp
in a solution binding assay. SLBP lacking either the entire
C-terminal domain (Figure 4B, lanes 13–15) or the first 89
amino acids (lanes 16–18) was able to interact with Imp/
Imp, albeit to a slightly reduced extent compared with
intact SLBP, whereas a protein lacking the first 127 amino
acids showed a significant impairment in binding Imp/
Imp (Figure 4B, lanes 19–21). Two of the predicted classical
NLSs (RKRR and KRKL) reside within the first 127 amino
acids, suggesting that these sequences may contribute to the
binding of SLBP to Imp. To test this, the RKRR and KRKL
sequences were mutated to alanines, yielding SLBPRKRR
and SLBPKRKL. Mutation of either of these sequences on
their own resulted in a reduction in binding by 50% (Fig-
ure 4B, lanes 4–9). Simultaneous mutation of both sequences
(SLBPRKRR/KRKL, lanes 10–12) caused a binding defect
nearly equivalent to that resulting from removing the entire
N-terminal domain (Figure 4B, lanes 19–21). Thus, both the
RKRR and KRKL sequences can mediate the association of
Imp/Imp through the N-terminal domain of SLBP.
Figure 3. In vitro import of SLBP by Trn-
SR2 and Imp/Imp. (A) HeLa cells
grown on coverslips were permeabilized
with digitonin and incubated with fluores-
cently-labeled GST-SLBP in the presence
of an energy regenerating system, buffer,
and Ran without or with the purified im-
port receptor indicated above or below
each panel. After 15 min of incubation, the
cells were washed to remove excess GST-
SLBP. The cells were fixed, mounted onto
microscope slides, and visualized using an
epifluorescence microscope. (B) Purified
GST-SLBP was tested for binding to im-
port receptors zz-Imp/Imp (lane 3), zz-
Imp (lane 4), and zz-Trn-SR2 (lane 5).
The purified E. coli expressed import re-
ceptors tagged with two copies of the IgG
binding domain or “z” domain of protein
A were recovered on IgG-Sepharose
beads. One-fifth of the eluted material was
run alongside 1/20 of the input GST-
SLBP. The background binding of GST-
SLBP to the IgG-Sepharose beads is shown
in lane 2. (C) In vitro-translated SLBP was
incubated with zz-Imp/Imp (lanes 3
and 4) or zz-Trn-SR2 (lanes 5 and 6).
RanQ69L was added to the reactions in
lanes 4 and 6. The proteins were bound to
IgG-Sepharose beads, and 20% of the
eluted material from each binding reaction was run on an 8% SDS-PAGE alongside 1/25 of the input SLBP (lane 1). The background binding
of SLBP to the IgG-Sepharose beads is shown in lane 2.
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As noted above, the C-terminal deletion mutant SLBPC70
demonstrated reduced binding to Imp/Imp (Figure 4B,
lanes 13–15), suggesting that the C-terminal domain of SLBP
may be involved in Imp/Imp association. To test the
involvement of the KVRH sequence in binding Imp/Imp,
we deleted the region of SLBP containing this sequence,
yielding SLBPC30. To address potential cooperation with
the other sites in SLBP, we also mutated the N-terminal
sequences individually and together in the SLBPC30 con-
struct. This series of SLBP mutants was then tested for the
ability to bind Imp/Imp and, as a negative control, Trn-
SR2. Deleting the last 30 amino acids from SLBP resulted in
an approximate 20% reduction in binding to Imp/Imp
relative to wild-type (Figure 4C, lanes 17–19), which is com-
parable with the reduction observed for the KRKL and
RKRR alanine substitution mutants (Figure 4C, lanes 1–12).
Introducing either the KRKL or RKRR mutation in
SLBPC30 resulted in an 80 and 74% reduction in associa-
tion with Imp/Imp relative to wild-type (Figure 4C, lanes
21–28). The RKRR/KRKL mutant exhibited a 90% reduction
in binding relative to wild-type SLBP (Figure 4C, lanes
13–15). Thus, combining the KRKL and RKRR mutations
with one another or with the C30 mutation resulted in a
similar defect in association with Imp/Imp. From these
observations, we conclude that the C-terminal KVRH se-
quence in SLBP also contributes to Imp/Imp binding, and
that severe impairment of binding requires mutation of two
of the three sites.
Sequences in SLBP Required for Imp Binding Are
Critical for the Nuclear Accumulation of SLBP In Vivo
To assess whether the sequences required for binding Imp
contributed to SLBP nuclear localization in vivo, constructs
were generated containing GFP fused to the N terminus of
either wild-type SLBP or SLBPs carrying mutations in the
three sequences. HeLa cells were transiently transfected
with each of the constructs, images were collected, and at
least 100 GFP-expressing cells per construct were scored for
fusion protein localization. Four categories were established
to describe the different localization phenotypes: 1) com-
pletely nuclear; 2) partially cytoplasmic, with higher
amounts in the nucleus; 3) evenly distributed between the
nucleus and the cytoplasm; and 4) completely cytoplasmic.
An example of each of these phenotypes is shown at the top
of the table in Figure 5A.
GFP-SLBPwt as well as GFP-SLBPKRKL were almost exclu-
sively nuclear (Figure 5A), whereas 15% of cells displayed
partial cytoplasmic localization when the RKRR sequence
was mutated (Figure 5A). Strikingly, GFP-SLBPRKRR/KRKL,
which is mutated for both N-terminal sequences, was evenly
distributed between the nucleus and cytoplasm in 65% of the
cells. This result thus demonstrates that both N-terminal
sequences can mediate the nuclear import of SLBP in vivo.
We next examined the potential role of the C-terminal
domain of SLBP in its nuclear localization. Indeed, GFP-
SLBPRKRR/KRKL/C70, which lacks the entire C-terminal do-
main, was evenly distributed in 80% of the cells, a 15%
increase relative to GFP-SLBPRKRR/KRKL. From these data,
we conclude that the N-terminal KRKL and RKRR se-
quences and perhaps the C-terminal domain of SLBP con-
tribute to SLBP nuclear localization in vivo. An explicit
analysis of the C-terminal region involved in import is given
below.
Despite the fact that the KRKL and RKRR sequences and
the C-terminal domain of SLBP seemed to be important for
GFP-SLBP’s nuclear localization, the mutant GFP-fusion
proteins were never exclusively cytoplasmic. This observa-
tion could be explained either by Transportin-SR2–mediated
import of SLBPs, which lack the putative Imp/Imp NLSs,
or diffusion of the GFP-SLBP. GFP-SLBPRKRR/KRKL and
GFP-SLBPRKRR/KRKL/C70 are 55 and 47 kDa, respectively,
raising the possible question as to whether they might be
small enough to diffuse in and out of the nucleus. To distin-
guish between these possibilities, a GST tag was added to
the N terminus of GFP-SLBP, yielding GST-GFP-SLBP,
which has a molecular mass of 90 kDa and is too large to
cross NPCs by diffusion. Western blot analysis with the GFP
antibody was carried out to compare the relative expression
level of each of the GST-GFP fusion constructs (Figure 5B,
left). Probing with the SLBP antibody revealed that the
expression of GST-GFP-SLBPwt was similar to the endoge-
nous SLBP (Figure 5B, right).
GST-GFP-SLBPwt and GST-GFP-SLBPKRKL demonstrated
similar localization to GFP-SLBPwt and GFP-SLBPKRKL (Fig-
ure 5, A and C), indicating that mutation of the KRKL
Figure 4. Mapping the sequences in SLBP required for Imp/
Imp binding. (A) The amino acid sequence of human SLBP is
shown with the RNA binding domain in italics. The predicted Imp
binding sites that were mutated to alanines are in bold. The arrows
above the sequence mark the amino acids at which the protein was
truncated either from the N-terminal end (N89 and N127) or the
C-terminal end (C70 and C30). (B) The different in vitro-trans-
lated SLBP truncation or site-specific mutants labeled with [35S]me-
thionine were incubated without import receptor (lanes 2, 5, 8, 11,
14, 17, and 20) or with zz-Imp/Imp (lanes 3, 6, 9, 12, 15, 18, and
21). Complexes were recovered on IgG-Sepharose beads and eluted
with sample buffer. Eluate (20%) was run on an 8% SDS-PAGE
alongside 1/25 of the input SLBP for each binding reaction (lanes 1,
4, 7, 10, 13, 16, and 19). I, input. (C) The different in vitro-translated
SLBP truncation or site-specific mutants labeled with [35S]methi-
onine were incubated without import receptor (lanes 2, 6, 10, 14, 18,
22, 26, and 30), with zz-Imp/Imp (lanes 3, 7, 11, 15, 19, 23, 27, and
31) or with zz-Trn-SR2 (lanes 4, 8, 12, 16, 20, 24, 28, and 32). The
samples were subsequently processed as in B.
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sequence alone had no effect on SLBP localization. In con-
trast, when the RKRR sequence was mutated in GST-GFP-
SLBP, the resulting protein (GST-GFP-SLBPRKRR) distrib-
uted evenly between the nucleus and cytoplasm in 22% of
cells and was completely cytoplasmic in 24% of cells (Figure
5, C and D). If the KRKL mutation was introduced simulta-
neously with the RKRR mutation in GST-GFP-SLBP (GST-
GFP-SLBPRKRR/KRKL), more of the cells showed cytoplasmic
localization than with the RKRR mutation alone, indicating
that the KRKL sequence does contribute to the import of
SLBP (Figure 5, C and D). Deleting the last 23 amino acids
from the C-terminal end of SLBP (GST-GFP-SLBPC23), just
beyond the KVRH sequence, did not affect SLBP’s nuclear
localization (Figure 5C). However, removing the next seven
amino acids containing the KVRH sequence (GST-GFP-
SLBPC30) resulted in a pattern of localization similar to
that observed for the RKRR mutant (Figure 5, C and D),
indicating that the KVRH sequence is important for SLBP
nuclear localization. Strikingly, when the two N-terminal se-
quences were mutated and the C-terminal KVRH sequence
was removed (GST-GFP-SLBPRKRR/KRKLC30), SLBP was ex-
cluded from the nucleus of all cells (Figure 5, C and D).
Although we had identified which sequences were re-
quired for SLBP nuclear localization, we did not know
whether these sequences were in fact NLSs. The proof for
NLS activity is the ability to direct a cytoplasmic protein into
the nucleus. Therefore, we fused each of the sequences to
GST-GFP, which is normally cytoplasmic (Figure 5E, top
row), and analyzed the localization of the fusion proteins.
The well-characterized SV40 NLS also was fused to GST-
GFP as a positive control (Figure 5E, second row). The
results of our analysis show that the KRKL and RKRR
sequences indeed have NLS activity (Figure 5E, third and
fourth rows), whereas the KVRH sequence does not (bottom
row). Thus, we conclude that the RKRR and KRKL se-
quences are bona fide NLSs and that the KVRH sequence is
not. Perhaps the KVRH sequence helps stabilize the interac-
tion between SLBP and Imp/ and for this reason is
needed for optimal import (see Discussion).
To determine which of the N-terminal NLSs contributed
most significantly to the nuclear localization defect of GST-
GFP-SLBPRKRR/KRKL/C30, the KRKL and RKRR sequences
were mutated individually in the context of the GST-GFP-
SLBPC30 construct (yielding GST-GFP-SLBPKRKL/C30 and
GST-GFP-SLBPRKRR/C30). GST-GFP-SLBPRKRR/C30 and
GST-GFP-SLBPKRKL/C30 were exclusively cytoplasmic in
43 and 25% of the cells examined (Figure 5, C and D), a 23
and 5% increase relative to GST-GFP-SLBPC30. These ob-
servations are consistent with those showing that GST-GFP-
SLBPRKRR was more severely impaired in nuclear localiza-
tion than GST-GFP-SLBPKRKL. From these observations, we
conclude that the C-terminal KVRH sequence and the RKRR
sequence make the largest contribution to the nuclear local-
ization of SLBP (see Discussion).
Trn-SR2 Does Not Import SLBP in HeLa Cells
We also determined which part of SLBP is required for
association with Trn-SR2. SLBP does not contain a conven-
tional RS domain as found in other import substrates of
representative localization phenotypes for the indicated GST-GFP–
tagged SLBP NLS mutants. (E) The predicted Imp / NLSs were
fused to the C terminus of GST-GFP and examined for NLS activity
by transient transfection. The construct transfected is indicated on
the right side of each row of panels.
Figure 5. In vivo localization of SLBP mutants impaired for Imp
binding. (A) Images of cells transiently transfected with the indi-
cated GFP-SLBP construct were collected and at least 100 cells per
construct were examined. Cells were scored for fusion protein lo-
calization and grouped into four categories: 1) exclusive nuclear
localization; 2) greater nuclear than cytoplasmic localization; 3) even
distribution between the nucleus and cytoplasm; or 4) exclusive
cytoplasmic localization. (B) Western blot analysis with an anti-GFP
antibody and anti-SLBP antibody, demonstrating the relative ex-
pression levels of the different GST-GFP–tagged SLBPs (top), and
the levels of the endogenous SLBP as a loading control (bottom).
The C-terminal GST-GFP-SLBP truncation mutants do not contain
the epitope recognized by the anti-SLBP antibody necessitating their
detection with the anti-GFP antibody (left, top). The expression of
GST-GFP-SLBPwt (lane 1) relative to the endogenous SLBP is shown
on the right. The asterisks mark the 75- and 90-kDa proteins that
cross-react with the SLBP antibody. (C) Images of cells transiently
transfected with the indicated GST-GFP-SLBP construct were col-
lected and at least 300 cells per construct were examined. The
number of independent transfections is indicated in the column
labeled n. Cells were scored as described in A. (D) Images of
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Trn-SR2, but it contains only a few dispersed SR dipeptides.
Candidate Trn-SR2 binding motifs in SLBP are shown in
bold in Figure 6A.
Importantly, we found that impairing the two N-terminal
Imp binding sites either independently or at the same time
had no effect on Trn-SR2 binding (Figure 4C, lanes 4, 8, 12,
and 16). As a first approach toward mapping the Trn-SR2
binding site(s), SLBP was serially truncated from the N
terminus (N68 and N76), removing portions of the pro-
tein containing the predicted binding sites. The resulting
proteins were then tested for the ability to interact with
Trn-SR2 in a solution binding assay. Through this analysis,
we found that the first 68 amino acids are dispensable for
Trn-SR2 binding (Figure 6B, lanes 1–3 and 25–27). However,
if the first 76 amino acids were deleted, there was a signif-
icant reduction in the association with Trn-SR2 (Figure 6B,
lanes 28–30). These data suggest that the region between
amino acids 68 and 76, which contains one of the predicted
Trn-SR2 binding sites, might be involved in recruiting Trn-
SR2 to SLBP. To test this hypothesis, the amino acids be-
tween residues 68 and 76 were substituted with alanines
(69–76). We also deleted the first 18 amino acids of SLBP
(N18 SLBP) and mutated the third potential Trn-SR2 bind-
ing site in the RNA binding domain to alanines (SRRS).
SLBP 69–76 demonstrated a 40% reduction in binding to
Trn-SR2 relative to wild-type SLBP (Figure 6B, lanes 1–6). In
contrast, the N18 mutation did not significantly interfere
with Trn-SR2 binding (Figure 6B, lanes 13–15). However,
because both of these sequences reside within the first 76
amino acids of SLBP, we tested whether combining these
two mutations (N18/69-76) would result in a Trn-SR2
binding defect similar to N76 SLBP. The association of
N18/69-76 SLBP with Trn-SR2 was reduced by 70% rel-
ative to wild-type (Figure 6B, lanes 16–18), but this mutant
was not as defective as N76 SLBP, which exhibited a 90%
reduction in binding to Trn-SR2 under the same conditions
(Figure 6B, lanes 28–30).
A final possible Trn-SR2 binding site is the SRRS se-
quence, which lies in the RNA binding domain of SLBP.
Mutation of this sequence did not interfere with Trn-SR2
binding (Figure 6B, lanes 7–9). However, when all three
predicted Trn-SR2 binding sites were mutated, the binding
of Trn-SR2 was reduced by 90% relative to wild-type
(Figure 6B, lanes 22–24). From these results, we conclude
that the binding of Trn-SR2 to SLBP occurs through an
extended region rather than a precise set of residues in the
first 76 amino acids of SLBP and also may involve the SRRS
sequence in the RNA binding domain.
Mutation of the three sequences in SLBP required for
binding to Imp/Imp, which was sufficient to completely
impair SLBP nuclear accumulation in vivo, did not affect
Trn-SR2 binding in vitro (Figure 4C, lane 32). These obser-
vations suggest that Trn-SR2 does not contribute to SLBP
import in vivo. Indeed, simultaneous mutation of all three
Trn-SR2 binding sites had no effect on SLBP nuclear local-
ization (our unpublished data). We reasoned that if Imp/
Imp represents the dominant import pathway for SLBP,
perhaps reducing the ability of SLBP to be imported by this
pathway may reveal any potential import activity of Trn-
SR2 toward SLBP in this system. To test this, we determined
whether mutating the N-terminal sequences that contribute
to Trn-SR2 binding added to the defect in nuclear localiza-
tion resulting from mutation of the two N-terminal Imp/
Imp NLSs. HeLa cells were transfected with GST-GFP-
SLBPRKRR/KRKL or GST-GFP-SLBPRKRR/KRKL/N18/69–76
and scored for fusion protein localization. There was no
significant difference in the localization of these two SLBPs
(Figure 6C). Thus, we conclude that Trn-SR2 is not involved
in SLBP nuclear import in HeLa cells.
SLBP Does Not Contain Nuclear Export Signals
SLBP present in the cytoplasm of S-phase cells is associated
with the histone messenger ribonucleoprotein particle
(mRNP) (Whitfield et al., 2004). Because SLBP is not required
for histone mRNA export (Erkmann et al., 2005), we consid-
ered it possible that it accompanies the histone mRNP to the
cytoplasm but is not actively exported. To test this hypoth-
esis, we used an interspecies heterokaryon assay to examine
the shuttling capabilities of wild-type SLBP (wt) and an
SLBP mutant (mut) that cannot bind histone mRNA
(Dominski et al., 2001). Human U2-OS cells were transfected
with either wt or mut GFP-SLBP and were subsequently
treated with protein synthesis inhibitors and fused to MEF
cells. Accumulation of the GFP-tagged protein in the mouse
Figure 6. Characterization of the sequences in SLBP needed for
Trn-SR2 binding. (A) The amino acid sequence of human SLBP is
shown with the RNA binding domain in italics. The sequence after
the RNA binding domain and before the last four amino acids of the
protein (SAMS) is not shown. The predicted Trn-SR2 binding sites
that were mutated to alanines are in bold. The arrows above the
sequence mark the amino acids at which the protein was truncated
from the N-terminal end (N18, N68, and N76). (B) The different
in vitro-translated SLBP truncation or site-specific mutants labeled
with [35S]methionine were incubated without import receptor (lanes
2, 5, 8, 11, 14, 17, 20, 23, 26, and 29) or with zz-Trn-SR2 (lanes 3, 6,
9, 12, 15, 18, 21, 24, 27, and 30). Samples were subsequently pro-
cessed as in Figure 4B. I, 1/25 of the input (lanes 1, 4, 7, 10, 13, 16,
19, 22, 25, and 28). (C) Images of cells transiently transfected with
the indicated GST-GFP-SLBP construct were collected, and at least
300 cells per construct were examined. The number of independent
transfections analyzed is indicated in the column labeled n. Cells
were scored as described in Figure 5A.
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nucleus of the heterokaryon indicates that the protein has
been exported out of the human nucleus into the shared
cytoplasm and imported into the mouse nucleus. A small
amount of GFP-SLBP wt relocalized to the mouse nucleus
after ninety minutes of incubation (Figure 7A), but GFP-
SLBP mut, which cannot bind histone mRNA, remained in
the human nucleus in the heterokaryon (Figure 7B). Thus,
SLBP does not contain any nuclear export signals and is
likely exported from the nucleus as a passive cargo of the
histone mRNP.
DISCUSSION
The processing-specific hSLBP orthologues that have been
cloned, Xenopus SLBP1 (xSLBP1), mouse SLBP, and Drosoph-
ila SLBP, are found in both the nuclear and cytoplasmic
compartments in oocytes and embryos (Wang et al., 1999;
Allard et al., 2002; Lanzotti et al., 2004). In addition, in
Xenopus oocytes a small fraction of xSLBP1 localizes to sub-
nuclear structures termed Cajal bodies, which are implicated
in histone gene transcription and mRNA processing (Abbott
et al., 1999). In this report, we describe the identification of
two import receptors that are able to import human SLBP
into HeLa nuclei in vitro and have determined the sequences
in SLBP necessary for its nuclear localization in vivo. Addi-
tionally, we have examined the changes in the localization of
SLBP during the cell cycle.
SLBP Localization during S Phase
During S phase, SLBP is localized predominantly in the
nucleus and does not seem to concentrate in Cajal bodies. In
cells arrested at the beginning of S phase, SLBP is nuclear.
As cells progress through S phase and the levels of histone
mRNA increase, SLBP partially redistributes to the cyto-
plasm. Previously, we have shown that the treatment of cells
with inhibitors of DNA replication, which results in the
degradation of histone mRNA, also results in SLBP localiz-
ing to the nucleus (Whitfield et al., 2004). These observations
therefore suggest that the cytoplasmic localization of SLBP
may result from its association with histone mRNAs in the
cytoplasm. In agreement with this interpretation, we find
that SLBP with a two-amino acid mutation that prevents
RNA binding is restricted to the nucleus (Figure 2A). Also,
using a heterokaryon assay, we show that SLBP incapable of
histone mRNA binding does not shuttle out of the nucleus
(Figure 7). Previous observations made in Drosophila em-
bryos also support the notion that the cytoplasmic localiza-
tion of SLBP requires histone mRNA production (Lanzotti et
al., 2004). During the early cell cycles of Drosophila develop-
ment, dSLBP persists throughout the cell cycle but its local-
ization varies with the phase of the cell cycle (Lanzotti et al.,
2002; Lanzotti et al., 2004). During S phase, when histone
mRNAs are made, dSLBP is present in both the cytoplasm
and nucleus, whereas in G1 and G2 phase, SLBP is exclu-
sively nuclear (Lanzotti et al., 2004).
At the end of S phase, human SLBP is degraded in a
phosphorylation-dependent manner (Whitfield et al., 2000;
Zheng et al., 2003). Treatment of cells with proteasome in-
hibitors prevents this degradation, resulting in the accumu-
lation of phosphorylated SLBP in G2 phase. SLBP containing
mutations in the phosphorylation sites responsible for trig-
gering its degradation is also stable in G2 phase. Interest-
ingly, we have found that various nondegraded forms of
SLBP are nuclear in G2 phase. These results, however, are in
contrast to what we previously observed by cellular frac-
tionation, which showed that phosphorylated SLBP from
G2-phase cells was exclusively cytoplasmic (Zheng et al.,
2003). We believe that our immunofluorescence studies ac-
curately reflect the localization of SLBP in G2-phase cells
because we obtained identical staining patterns in these cells
using antibodies targeting both the N- and C-terminal ends
of the protein. Therefore, epitope masking can be ruled out
as the reason for not detecting SLBP in the cytoplasm of
G2-phase cells. SLBP is only 28 kDa, which is below the size
threshold for diffusion through NPCs. Therefore, the pres-
ence of SLBP in cytoplasmic extracts from G2 cells is most
likely due to its diffusion out of the nucleus during the
fractionation procedure. We note that in the cellular frac-
tionation experiments (Zheng et al., 2003), only the phos-
phorylated form of SLBP was entirely cytoplasmic, whereas
the unphosphorylated form was present in both the nuclear
and cytoplasmic fractions. Most likely, unphosphorylated
SLBP was retained in the nuclear fraction by associating
with either a subnuclear structure or macromolecular com-
plex that is incapable of diffusing through nuclear pores.
Figure 7. SLBP does not contain nuclear export signals. U2-OS
cells were transfected with plasmids expressing GFP-SLBP wt (A) or
the RNA binding mutant GFP-SLBP mut (B), which contains two
tyrosines in the RBD replaced with alanines (Dominski et al., 2001).
Twenty-four hours after transfection, the cells were washed and
fused to wild-type MEF cells, and de novo protein synthesis was
blocked by cycloheximide. Ninety minutes after fusion, the cells
were fixed and stained with an antibody to human Ku antigen
followed by staining with a Texas Red-conjugated secondary anti-
body. The heterokaryons were photographed. Nuclei of human (h)
and mouse (m) origin are identified by DAPI staining. Mouse nuclei
are indicated with white arrows.
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Multiple Sequences in SLBP Mediate Imp/Imp
Association
We have determined that Imp/Imp interacts with SLBP
and can import it in vitro. Consistent with this observation,
Imp/Imp was dissociated from SLBP by RanGTP. We
mapped three sequences in SLBP (RKRR, KRKL, and KVRH)
that mediate the interaction with Imp/Imp. One of these
sequences (KVRH) is more distant than the other two from
the SV40 NLS, because it contains only two basic residues.
We have determined that, although this sequence is impor-
tant for binding to Imp and the nuclear localization of
SLBP in vivo, it does not possess NLS activity when fused to
a heterologous protein. We interpret these data to mean that
the KVRH sequence is necessary for optimal Imp/ asso-
ciation but is probably not a binding site for the receptor.
Perhaps it helps stabilize the interaction between SLBP and
Imp/ and for this reason is needed for optimal import.
Single mutation of the N-terminal (RKRR) and the C-termi-
nal (KVRH) sequences resulted in similar reductions in
SLBP nuclear localization in vivo. In contrast, mutating the
N-terminal KRKL sequence had no effect on the localization
of SLBP, despite our demonstration that this sequence is a
functional NLS. The activity of the KRKL sequence as an
NLS was revealed only if the RKRR NLS also was mutated,
whether it be in the GST-GFP-SLBPRKRR/KRKL or GST-GFP-
SLBPRKRR/KRKL/C30 construct. The KRKL sequence is also
a cyclin A/cdk2 binding site, required for SLBP phosphor-
ylation and degradation (Zheng et al., 2003; Koseoglu, un-
published data). These observations therefore suggest that
perhaps the KRKL sequence is not the preferred NLS in the
wild-type protein, but only is used in the absence of the
nearby RKRR Imp/Imp binding site. In sum, we have
identified two NLSs in SLBP (KRKL and RKRR) and a third
sequence (KVRH) that contributes to SLBP nuclear localiza-
tion.
SLBP Binding and Import by Trn-SR2
We have demonstrated that complexes containing Trn-SR2
and SLBP form efficiently in vitro and are dissociated by
Ran-GTP. In an in vitro import assay, in which other import
receptors were unable to import SLBP, Trn-SR2 efficiently
imported SLBP. Despite this in vitro activity, we find that
Trn-SR2 does not play a role in the import of SLBP in HeLa
cells. The best evidence for this is that SLBP containing
mutations in the three sequences required for Imp/Imp
binding is exclusively present in the cytoplasm, although it
retains its full ability to bind to Trn-SR2. Although we were
not able to precisely map the Trn-SR2 binding site, the
N18/69-76 mutant, which had reduced Trn-SR2 binding in
vitro, was not defective in nuclear localization. Moreover,
combining this mutation with mutations in the two Imp
NLSs resulted in no further decrease in the nuclear localiza-
tion of SLBP compared with SLBP lacking only the two
Imp NLSs. It remains possible that Trn-SR2 has a role in
SLBP nuclear localization perhaps during a specific stage in
development or in a particular cell type.
Model for SLBP Localization
Together, our data suggest a model for SLBP localization
where SLBP is imported into the nucleus by Imp/Imp,
and the cytoplasmic accumulation of SLBP is dependent on
the presence of histone mRNA. We have recently shown that
neither SLBP nor the 3 end of histone mRNA is essential for
histone mRNA export (Erkmann et al., 2005). Thus, it is most
probable that after histone pre-mRNA processing in the
nucleus SLBP is exported to the cytoplasm as a passive cargo
of the histone mRNA. SLBP present in the cytoplasm then
participates in histone mRNA translation (Sanchez and Mar-
zluff, 2002). As histone mRNAs turnover in the cytoplasm,
SLBP reenters the nucleus (Whitfield et al., 2004). At the end
of S phase, SLBP is degraded by a phosphorylation-depen-
dent mechanism requiring cyclin A/cdk 2 (Zheng et al.,
2003). Because histone mRNA decay does not require the
prior degradation of SLBP (Whitfield et al., 2004), it is pos-
sible that SLBP is degraded in the nucleus after dissociation
from the mRNA.
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